Immune checkpoint inhibitors are superior to docetaxel as second-line therapy for patients with non-small cell lung carcinoma.

Fillon, Mike

Immune checkpoint inhibitors are superior to docetaxel as second-line therapy for patients with non-small cell lung carcinoma. [electronic resource] - CA: a cancer journal for clinicians 05 2018 - 178-179 p. digital

Publication Type: Journal Article; Comment

1542-4863

10.3322/caac.21423 doi


Carcinoma, Non-Small-Cell Lung
Docetaxel
Humans
Lung Neoplasms